Posted On: 01/04/2015 11:34:12 AM
Post# of 30066
Piramal Imaging - another potential acquisition target
http://www.thechairmansblog.com/amarantus-bio...OSrK3.dpuf
Quote:
"On March 20th, 2014, the FDA approved an amyloid imaging agent being developed by Piramal Imagings' Neuraceq®, the third such approval at the FDA on the heels of approvals for Avid Radiopharmaceuticals and GE. We believe this approval represents a shift in the agency’s thinking regarding biomarkers for Alzheimer’s disease, and is a statement regarding the importance of new products in the quickly evolving ‘gold standard’ in-life diagnostic paradigm for Alzheimer’s disease."
http://www.thechairmansblog.com/amarantus-bio...OSrK3.dpuf
(0)
(0)
